NEW! 52-week data and FDA-approved with a once-daily dosing option.1
NEW! 52-week data and
FDA-approved with a once-daily dosing option.1
Please see Full Prescribing Information for details.
NEW! 52-week data and FDA-approved with a once-daily dosing option.1
NEW! 52-week data and
FDA-approved with a once-daily dosing option.1
Please see Full Prescribing Information for details.
Steroid-free EUCRISA provides efficacy and can be used as part of a long-term treatment plan1,2
EUCRISA has a dosing regimen that can be adjusted to fit your patient's needs1
EUCRISA has safety data across 5 studies, including pivotal and open-label safety extension studies, and an open-label infant safety study1,3
EUCRISA is now FDA-approved with an expanded dosing recommendation to consider once-daily application once clinical effect has been achieved with twice-daily application1
EUCRISA is now
FDA-approved with an expanded dosing recommendation to consider once-daily application once clinical effect has been achieved with twice-daily application1
EUCRISA is now
FDA-approved with an expanded dosing recommendation to consider once-daily application once clinical effect has been achieved with twice-daily application1
Register or sign in to check availability and request samples
Nana is a dancer who has had mild-to-moderate atopic dermatitis for more than 30 years
Register or sign in to check availability and request samples
EUCRISA is covered for approximately 95% of commercially-insured lives. Check the cost and coverage options in your area
EUCRISA is now
FDA-approved with an expanded dosing recommendation to consider once-daily application once clinical effect has been achieved with twice-daily application1
EUCRISA is covered for approximately 95% of commercially-insured lives. Check the cost and coverage options in your area
Learn more about a 28-day, single-arm, open-label study in 3 to <24 month old patients2
*Eligible patients pay as little as $10
Learn more about the safety data of EUCRISA from the 4-week pivotal trials and open-label safety extension study1,2
EUCRISA has proven efficacy across all pivotal trial primary and secondary endpoints in patients aged 2 years and up1,3
Learn more about a 28-day, single-arm, open-label safety study in 3- to <24-month-old patients 4
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2023 Pfizer Inc. All rights reserved.
EUCRISA (crisaborole) is indicated for topical treatment of mild-to-moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.
EUCRISA is for topical use only and is not for ophthalmic, oral, or intravaginal use. For more information, please view the full prescribing information here.
Contraindications
EUCRISA is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation.
Warnings and Precautions
Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with EUCRISA and should be suspected in the event of severe pruritus, swelling, and erythema at the application site or at a distant site. Discontinue EUCRISA immediately and initiate appropriate therapy if signs and symptoms of hypersensitivity occur.
Adverse Reactions
The most common treatment-related adverse reaction occurring in clinical trials was application site pain, such as burning or stinging.
Please see Full Prescribing Information and Patient Information